Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2007

Primary Completion Date

April 17, 2008

Study Completion Date

April 17, 2008

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

GSK716155 for injection

GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.

DRUG

Placebo

Subjects will also receive placebo.

Trial Locations (3)

812-0025

GSK Investigational Site, Fukuoka

130-0004

GSK Investigational Site, Tokyo

160-0017

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00530309 - Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter